Antibody–drug conjugates: the future of targeted cancer therapies

Antibody–drug conjugates (ADCs) are at the forefront of targeted cancer therapies. These ‘smart’ therapies combine precision targeting with potent chemotherapy and offer hope for patients living with cancer. What are ADCs – and why do they matter? ADCs are known as ‘smart bombs’ or ‘biological missiles’ for cancer. They consist of three components: a monoclonal […]
